<?xml version="1.0" encoding="UTF-8"?>
<rss version="2.0" xmlns:atom="http://www.w3.org/2005/Atom">
<channel>
<title>Fate Therapeutics Inc — News on 6ix</title>
<link>https://6ix.com/company/fate-therapeutics-inc</link>
<description>Latest news and press releases for Fate Therapeutics Inc on 6ix.</description>
<language>en-us</language>
<lastBuildDate>Thu, 16 Apr 2026 13:00:00 GMT</lastBuildDate>
<generator>6ix RSS</generator>
<atom:link href="https://6ix.com/rss/company/fate-therapeutics-inc" rel="self" type="application/rss+xml" />
<image>
<url>https://6ix-events-pro.s3.amazonaws.com/6ixvideo/logos/org-logo6835671a78dffbe2df0f0c9d.webp</url>
<title>Fate Therapeutics Inc</title>
<link>https://6ix.com/company/fate-therapeutics-inc</link>
</image>
<item>
<title>Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR Annual Meeting</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-data-presentation-of-ft839-next-generation-off-the-shelf-car-t-cell-product-candidate-for-the-broad-treatment-of-hematological-malignancies-and-autoimmune-diseases-without-the-need-for-conditioning-chemotherapy-at-the-aacr-annual-meeting</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-data-presentation-of-ft839-next-generation-off-the-shelf-car-t-cell-product-candidate-for-the-broad-treatment-of-hematological-malignancies-and-autoimmune-diseases-without-the-need-for-conditioning-chemotherapy-at-the-aacr-annual-meeting</guid>
<pubDate>Thu, 16 Apr 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, April 16, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that preclinical data from the Company’s next-generation, off-the-shelf CAR T-cell product candidate, FT839, will be featured at the American Association for Cancer Research Annual Meet</description>
</item>
<item>
<title>Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological Malignancies and Autoimmune Diseases Without the Need for Conditioning Chemotherapy at the AACR ...</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-data-presentation-of-ft839-next-generation-off-the-shelf-car-t-cell-product-candidate-for-the-broad-treatment-of-hematological-malignancies-and-autoimmune-diseases-without-the-need-for-conditioning-chemotherapy-at-the-aacr</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-data-presentation-of-ft839-next-generation-off-the-shelf-car-t-cell-product-candidate-for-the-broad-treatment-of-hematological-malignancies-and-autoimmune-diseases-without-the-need-for-conditioning-chemotherapy-at-the-aacr</guid>
<pubDate>Thu, 16 Apr 2026 04:00:00 GMT</pubDate>
<description>Fate Therapeutics Announces Data Presentation of FT839 Next-Generation Off-The-Shelf CAR T-Cell Product Candidate for the Broad Treatment of Hematological</description>
</item>
<item>
<title>Fate Therapeutics to Participate in Upcoming Second Quarter 2026 Conferences</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-to-participate-in-upcoming-second-quarter-2026-conferences</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-to-participate-in-upcoming-second-quarter-2026-conferences</guid>
<pubDate>Thu, 09 Apr 2026 13:00:00 GMT</pubDate>
<description>SAN DIEGO, April 09, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in five upcoming investor conferences in the second quarter of 2026. 25th Annual Needham Virtual Healthcare Conference Location: Virtual Date: April 14t</description>
</item>
<item>
<title>Fate Therapeutics to Participate in Leerink Partners 2026 Global Healthcare Conference</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-to-participate-in-leerink-partners-2026-global-healthcare-conference</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-to-participate-in-leerink-partners-2026-global-healthcare-conference</guid>
<pubDate>Tue, 03 Mar 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, March 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that management will participate in a fireside chat and host investor meetings at the Leerink Partners 2026 Global Healthcare Conference on Monday, March 9, 2026 in Miami, Florida. Mana</description>
</item>
<item>
<title>Fate Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-fourth-quarter-and-full-year-2025-financial-results-and-business-updates</guid>
<pubDate>Thu, 26 Feb 2026 05:00:00 GMT</pubDate>
<description>Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day</description>
</item>
<item>
<title>Fate Therapeutics Reports New Employee Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-employee-inducement-210500968</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-employee-inducement-210500968</guid>
<pubDate>Tue, 03 Feb 2026 21:05:00 GMT</pubDate>
<description>SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a first-in-class pipeline of induced pluripotent stem cell (iPSC)-derived cellular immunotherapies to patients with cancer and autoimmune diseases, today announced that on February 1, 2026, the Company granted to one newly-hired non-executive employee (i) non-qualified stock options to purchase a total of 120,000 shares of the Company’s common stoc</description>
</item>
<item>
<title>Fate Therapeutics Presents Updated Phase 1 Clinical Data of FT819 Off-the-shelf CAR T-cell Product Candidate for Systemic Lupus Erythematosus and Preclinical Advances in Next-Generation Off-the-Shelf CAR T-cell Programs</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-presents-updated-phase-1-clinical-data-ft819-shelf-car-t-cell</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-presents-updated-phase-1-clinical-data-ft819-shelf-car-t-cell</guid>
<pubDate>Mon, 08 Dec 2025 05:00:00 GMT</pubDate>
<description>FT819 continues to demonstrate meaningful decrease in disease and favorable safety profile with twelve systemic lupus erythematosus (SLE) patients now</description>
</item>
<item>
<title>Fate Therapeutics to Present at Piper Sandler 37th Annual Healthcare Conference</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-present-piper-sandler-37th-annual-healthcare-conference-2025-11-25</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-present-piper-sandler-37th-annual-healthcare-conference-2025-11-25</guid>
<pubDate>Tue, 25 Nov 2025 05:00:00 GMT</pubDate>
<description>SAN DIEGO, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (the “Company” or “Fate Therapeutics”) (NASDAQ: FATE), a clinical-stage biopharmaceutical</description>
</item>
<item>
<title>Fate Therapeutics Reports Third Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-third-quarter-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-third-quarter-2025-financial-results-and-business-updates</guid>
<pubDate>Thu, 13 Nov 2025 05:00:00 GMT</pubDate>
<description>Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf</description>
</item>
<item>
<title>Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-presents-new-clinical-data-acr-convergence-2025-demonstrating</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-presents-new-clinical-data-acr-convergence-2025-demonstrating</guid>
<pubDate>Sun, 26 Oct 2025 04:00:00 GMT</pubDate>
<description>As of a September 25, 2025 data cut-off-date, 10 patients with treatment-refractory, moderate-to-severe Systemic Lupus Erythematosus (SLE) were treated with a</description>
</item>
<item>
<title>Fate Therapeutics Expands Leadership Team with Appointment of Kamal Adawi as Chief Financial Officer</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-expands-leadership-team-appointment-kamal-adawi-chief-financial</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-expands-leadership-team-appointment-kamal-adawi-chief-financial</guid>
<pubDate>Tue, 14 Oct 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE) (the Company), a clinical-stage biopharmaceutical company dedicated to</description>
</item>
<item>
<title>Fate Therapeutics to Present at Upcoming Investor Conferences</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-present-upcoming-investor-conferences-2025-08-25</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-present-upcoming-investor-conferences-2025-08-25</guid>
<pubDate>Mon, 25 Aug 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, Aug. 25, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a</description>
</item>
<item>
<title>Fate Therapeutics Reports Second Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-second-quarter-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-second-quarter-2025-financial-results-and-business-updates</guid>
<pubDate>Tue, 12 Aug 2025 04:00:00 GMT</pubDate>
<description>First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated</description>
</item>
<item>
<title>OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/osr-holdings-appoints-dr-andreas-niethammer-as-chief-medical-officer-of-vaximm-ag-an-osr-company-1</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/osr-holdings-appoints-dr-andreas-niethammer-as-chief-medical-officer-of-vaximm-ag-an-osr-company-1</guid>
<pubDate>Tue, 15 Jul 2025 11:30:00 GMT</pubDate>
<description>OSR Holdings, Inc. (NASDAQ: OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. .</description>
</item>
<item>
<title>Fate Therapeutics Announces Updated Clinical Data for FT819 Off-the-shelf CAR T-cell Product Candidate Demonstrating Durability of Drug-free Remission for Severe Lupus Nephritis at EULAR 2025 Congress</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-updated-clinical-data-ft819-shelf-car-t-cell-product</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-updated-clinical-data-ft819-shelf-car-t-cell-product</guid>
<pubDate>Wed, 11 Jun 2025 04:00:00 GMT</pubDate>
<description>All three patients treated with FT819 following fludarabine-free conditioning regimen for severe lupus nephritis achieve Primary Efficacy Renal Response</description>
</item>
<item>
<title>Fate Therapeutics Appoints Matthew Abernethy, M.B.A., to its Board of Directors</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-appoints-matthew-abernethy-mba-its-board-directors-2025-05-30-1</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-appoints-matthew-abernethy-mba-its-board-directors-2025-05-30-1</guid>
<pubDate>Fri, 30 May 2025 04:00:00 GMT</pubDate>
<description>SAN DIEGO, May 30, 2025 (GLOBE NEWSWIRE) -- Fate Therapeutics, Inc. (NASDAQ: FATE), a clinical-stage biopharmaceutical company dedicated to bringing a</description>
</item>
<item>
<title>Fate Therapeutics Announces Phase 1 Data Presentation of FT819 Off-the-Shelf CAR T-cell Product Candidate for SLE at EULAR 2025 Congress</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-phase-1-data-presentation-ft819-shelf-car-t-cell-product</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-phase-1-data-presentation-ft819-shelf-car-t-cell-product</guid>
<pubDate>Wed, 28 May 2025 04:00:00 GMT</pubDate>
<description>Oral presentation of clinical data from FT819 Phase 1 study highlights safety and efficacy of fludarabine-free treatment paradigm in moderate-to-severe</description>
</item>
<item>
<title>Fate Therapeutics Reports First Quarter 2025 Financial Results and Business Updates</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-first-quarter-2025-financial-results-and-business-updates</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-reports-first-quarter-2025-financial-results-and-business-updates</guid>
<pubDate>Tue, 13 May 2025 04:00:00 GMT</pubDate>
<description>Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral</description>
</item>
<item>
<title>Fate Therapeutics Announces Five Presentations on Off-the-Shelf CAR T-cell Product Platform at ASGCT Annual Meeting</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-five-presentations-shelf-car-t-cell-product-platform</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-announces-five-presentations-shelf-car-t-cell-product-platform</guid>
<pubDate>Tue, 29 Apr 2025 04:00:00 GMT</pubDate>
<description>Updated clinical and preclinical data showcase iPSC-derived off-the-shelf CAR T-cell therapy products for conditioning chemotherapy-free treatment across</description>
</item>
<item>
<title>Fate Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for FT819 to Treat Moderate to Severe Systemic Lupus Erythematosus (SLE)</title>
<link>https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-designation</link>
<guid isPermaLink="true">https://6ix.com/company/fate-therapeutics-inc/news/fate-therapeutics-receives-regenerative-medicine-advanced-therapy-rmat-designation</guid>
<pubDate>Mon, 14 Apr 2025 04:00:00 GMT</pubDate>
<description>– Recognizes potential of off-the-shelf CAR T-cell therapy to address significant unmet need and enables increased dialogue with FDA throughout the</description>
</item>
</channel>
</rss>